文献速递肝病消化道肿瘤与早癌

模拟肝细胞癌监测的获益与危害:为知情选择提供信息

Modeling the benefits and harms of surveillance for hepatocellular carcinoma: Information to support informed choices.
PubMed 文献 · Hepatology · 2017-10-11

该研究用马尔可夫模型模拟50岁代偿期肝硬化患者进入超声监测的结局,每1000例监测5年较不监测减少13例死亡(95%CI 12-14),需筛查77例预防1例肝癌死亡;但每1000例中150例(95%CI 146-154)出现假阳性,需伤害7例,65例需额外不必要的CT或MRI,39例需不必要的肝活检。

要点

  • 每1000例代偿期肝硬化患者监测5年,较不监测减少13例死亡(95%CI 12-14)。
  • 每1000例中150例(95%CI 146-154)出现至少一次假阳性,需伤害7例。
  • 假阳性导致65例需额外不必要的CT或MRI,39例需不必要的肝活检。

核心结论

  • 肝细胞癌监测的绝对死亡获益较小,而假阳性检测导致的危害在数量上更频繁,二者之间存在平衡。
  • 实施近期修订的美国肝病研究学会推荐预计可减少不必要的肝活检带来的危害。

研究设计与样本

  • 研究构建马尔可夫模型,模拟50岁代偿期肝硬化患者进入超声监测的结局。
  • 超声监测发现局灶性病变后,按欧洲肝病研究学会/欧洲癌症研究与治疗组织召回策略定义进一步检查。
  • 获益与危害结局以每1000例患者5年为单位表达。

主要发现

  • 每1000例监测5年较不监测减少13例死亡(95%CI 12-14),需筛查77例预防1例肝癌死亡。
  • 每1000例中150例(95%CI 146-154)出现至少一次假阳性检测,需伤害7例。
  • 因假阳性检测,65例需至少一次额外不必要的CT或MRI,39例需不必要的肝活检。
  • 监测获益对肝细胞癌发病率和治疗所达成的死亡获益敏感。
  • 危害对假阳性检测率和肝活检频率敏感。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Surveillance by ultrasonography for hepatocellular carcinoma (HCC) for individuals with cirrhosis is recommended. There is debate regarding the effectiveness of surveillance in reducing mortality, and there is little information on the harms available to patients considering surveillance. The aim of this study was to provide estimates of both the benefit and harms of surveillance. A Markov model was built to simulate outcomes of individuals aged 50 years with well-compensated cirrhosis entering surveillance. Following identification of a focal lesion by ultrasound surveillance, further investigations were defined by the European Association for the Study of the Liver/European Organization for Research and Treatment of Cancer recall policy. Benefit and harm outcomes are expressed per 1,000 patients over 5 years. For every 1,000 patients in surveillance over 5 years, there are 13 fewer deaths (95% confidence interval [CI], 12-14) compared with no surveillance, equating to a number needed to screen to prevent one death from HCC of 77. In comparison, many more individuals experienced harm through surveillance. For every 1,000 patients, 150 (95% CI, 146-154) had one or more false-positive tests equating to a number needed to harm from surveillance of 7. As a consequence of a false-positive test, 65 individuals required at least one additional unnecessary computed tomography scan or magnetic resonance imaging and 39 required an unnecessary liver biopsy according to the recall policy. Surveillance benefits were sensitive to the incidence of HCC and the mortality benefit achieved by treatment. Harms were sensitive to the rates of false-positive testing and the frequency of liver biopsy. CONCLUSION: There is a balance between the small absolute mortality benefit to surveillance for HCC and the numerically more frequent harms resulting from false-positive testing. Implementation of the recently revised American Association for the Study of Liver Diseases recommendations is predicted to reduce harms from unnecessary liver biopsy. (Hepatology 2017;66:1546-1555).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Taylor EJ, Jones RL, Guthrie JA, et al. Modeling the benefits and harms of surveillance for hepatocellular carcinoma: Information to support informed choices. Hepatology. 2017. PMID: 28605060. doi:10.1002/hep.29315

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。